|Videos|October 11, 2016
Atopic Dermatitis: Reimbursement Challenges
Advertisement
Episodes in this series
Panelists Peter L. Salgo, MD; Ed Pezalla, MD, MPH; Jeffrey D. Dunn, PharmD, MBA; Cheryl Allen, BS Pharm, MBA; and Jonathan Silverberg, MD, PhD, MPH, outline translating clinical trial results and some of the reimbursement challenges when treating patients with atopic dermatitis.
Advertisement
Related to this article
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
2
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
5